Entera Bio Ltd.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ENTX research report →
Companywww.enterabio.com
Entera Bio Ltd. , a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures.
- CEO
- Miranda J. Toledano
- IPO
- 2018
- Employees
- 18
- HQ
- Jerusalem, IL
Price Chart
Valuation
- Market Cap
- $61.04M
- P/E
- -4.78
- P/S
- 0.00
- P/B
- 5.54
- EV/EBITDA
- -4.62
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -87.97%
- ROIC
- -106.53%
Growth & Income
- Revenue
- $42.00K · -76.80%
- Net Income
- $-11,439,000 · -19.89%
- EPS
- $-0.25 · 0.00%
- Op Income
- $-11,529,000
- FCF YoY
- -9.62%
Performance & Tape
- 52W High
- $3.22
- 52W Low
- $0.91
- 50D MA
- $1.21
- 200D MA
- $1.77
- Beta
- 1.55
- Avg Volume
- 170.07K
Get TickerSpark's AI analysis on ENTX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 7, 26 | Galitzer Hillel | other | 72,993 |
| May 7, 26 | Yaacov-Garbeli Dana | other | 58,394 |
| May 7, 26 | Burshtein Gregory | other | 87,591 |
| Mar 9, 26 | Germano Geno J | buy | 20,000 |
| Mar 5, 26 | Ellis Sean | buy | 10,000 |
| Feb 10, 26 | Taitel Haya | buy | 7,500 |
| Feb 10, 26 | Germano Geno J | buy | 20,000 |
| Feb 9, 26 | Ellis Sean | buy | 18,000 |
| Feb 4, 26 | Germano Geno J | other | 0 |
| Jan 1, 26 | OSTROV GERALD M | other | 28,721 |
Our ENTX Coverage
We haven't published any research on ENTX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ENTX Report →